This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Newlands, E. S. Articles by Rustin, G. J. S. Search for Related Content PubMed PubMed Citation Articles by Newlands, E. S. Articles by Rustin, G. J. S.

Etoposide and Cisplatin/Etoposide, Methotrexate, and Actinomycin D (EMA) Chemotherapy for Patients With High-Risk Gestational Trophoblastic Tumors Refractory to EMA/Cyclophosphamide and Vincristine Chemotherapy and Patients Presenting With Metastatic Placental Site Trophoblastic Tumors

From the Department of Medical Oncology, Charing Cross Hospital, London, United Kingdom.

Address reprint requests to E.S. Newlands, Department of Medical Oncology, Charing Cross Hospital, Fulham Palace Rd, London W6 8RF, United Kingdom; email e.newlands{at}ic.ac.uk

PURPOSE: To evaluate the results of etoposide, cisplatin/etoposide, methotrexate, and actinomycin D (EP/EMA) chemotherapy in patients with gestational trophoblastic tumors (GTTs), who have relapsed after or who have become refractory to EMA/cyclophosphamide and vincristine (CO) chemotherapy, and in patients presenting with metastatic placental site trophoblastic tumors (PSTTs).

PATIENTS AND METHODS: We have treated a total of 34 patients with GTT and eight patients with metastatic PSTT with the EP/EMA chemotherapy schedule.

RESULTS: Twenty-two patients received EP/EMA because of apparent drug resistance to EMA/CO, and because the human chorionic gonadotropin (hCG) was near normal, they were not assessable for response. Twenty-one of these patients (95%) are alive and in remission. In the group where the hCG was high enough to confirm a response (greater than one log fall in hCG) to EP/EMA, all 12 patients responded and nine of these patients (75%) are alive and in remission. We have treated three patients with PSTT where the interval from antecedent pregnancy was less than 2 years, and all patients (100%) are alive and in remission. We have treated five patients where the interval from antecedent pregnancy was greater than 2 years and one fifth (20%) remain in remission. The survival for patients with GTT is 30 (88%) out of 34 patients and four (50%) out of eight patients for PSTT, giving an overall survival for these two cohorts of 34 (81%) out of 42 patients. The toxicity of this schedule is significant, with grade 3 or 4 toxicity (National Cancer Institute common toxicity criteria) recorded in hemoglobin (21%), WBC (68%), and platelets (40%). The role of surgery in this group of patients is important and contributed to sustained remission in five patients (23%) and possibly helped an additional seven patients (32%).

CONCLUSION: EP/EMA is an effective but moderately toxic regimen for patients with high-risk GTT who become refractory to or relapse from EMA/CO chemotherapy. Also, EP/EMA clearly has activity in patients with metastatic PSTT.

The Choriocarcinoma Service is funded by the National Specialist Commissioning Advisory Group of the Department of Health, London, United Kingdom.

This article has been cited by other articles:

				J. Wang, D. Short, N. J. Sebire, I. Lindsay, E. S. Newlands, P. Schmid, P. M. Savage, and M. J. Seckl Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE) Ann. Onc., September 1, 2008; 19(9): 1578 - 1583. [Abstract] [Full Text] [PDF]

				K. Collier, C. Schink, A. M. Young, K. How, M. Seckl, and P. Savage Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 51 - 55. [Abstract] [PDF]

				Errata Obstet. Gynecol., April 1, 2004; 103(4): 799 - 799. [Full Text] [PDF]

				I. A. McNeish, S. Strickland, L. Holden, G. J.S. Rustin, M. Foskett, M. J. Seckl, and E. S. Newlands Low-Risk Persistent Gestational Trophoblastic Disease: Outcome After Initial Treatment With Low-Dose Methotrexate and Folinic Acid From 1992 to 2000 J. Clin. Oncol., April 1, 2002; 20(7): 1838 - 1844. [Abstract] [Full Text] [PDF]